Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae

被引:51
作者
Batt, SL
Charalambous, BM
Solomon, AW
Knirsch, C
Massae, PA
Safari, S
Sam, NE
Everett, D
Mabey, DCW
Gillespie, SH
机构
[1] UCL, Dept Med Microbiol, London NW3 2PF, England
[2] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England
[3] Pfizer Inc, New York, NY 10017 USA
[4] Kilimanjaro Christian Med Coll, Clin Lab, Moshi, Tanzania
关键词
D O I
10.1128/AAC.47.9.2765-2769.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Community distribution of azithromycin has an important role to play in trachoma control. Previous studies have suggested that this may increase the prevalence of macrolide-resistant Streptococcus pneumoniae. S. pneumoniae was isolated from children under 7 years of age in Rombo District, northern Tanzania, before and 2 and 6 months after community-wide administration of azithromycin. Overall carriage rates were 11, 12, and 7%, respectively. Only one macrolide-resistant isolate carrying the mef gene was obtained 6 months after azithromycin administration. This contrasted with cotrimoxazole and penicillin resistance, both of which were common (cotrimoxazole resistance, 42, 43, and 47%, and penicillin resistance, 21, 17, and 16% at baseline, 2 months, and 6 months, respectively). There was a significant association between cotrimoxazole and penicillin resistance (P < 0.0001, Fisher's exact). These data suggest that in communities where macrolide resistance is rare, azithromycin distribution for trachoma control is unlikely to increase the prevalence of resistant organisms.
引用
收藏
页码:2765 / 2769
页数:5
相关论文
共 26 条
  • [1] EFFECT OF AZITHROMYCIN ON PHARYNGEAL, MICROFLORA
    ADEGBOLA, RA
    MULHOLLAND, EK
    BAILEY, R
    SECKA, O
    SADIQ, T
    GLASGOW, K
    MABEY, D
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1995, 14 (04) : 335 - 336
  • [2] Arason VA, 1996, BMJ-BRIT MED J, V313, P387
  • [3] RANDOMIZED CONTROLLED TRIAL OF SINGLE-DOSE AZITHROMYCIN IN TREATMENT OF TRACHOMA
    BAILEY, RL
    ARULLENDRAN, P
    WHITTLE, HC
    MABEY, DCW
    [J]. LANCET, 1993, 342 (8869) : 453 - 456
  • [4] BOWMAN RJ, 2000, INVESTIG OPHTHALMOL, V41, P4079
  • [5] Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area
    Chern, KC
    Shrestha, SK
    Cevallos, V
    Dhami, HL
    Tiwari, P
    Chern, L
    Whitcher, JP
    Lietman, TM
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 1999, 83 (12) : 1332 - 1335
  • [6] A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children
    Dawson, CR
    Schachter, J
    Sallam, S
    Sheta, A
    Rubinstein, RA
    Washton, H
    [J]. CLINICAL INFECTIOUS DISEASES, 1997, 24 (03) : 363 - 368
  • [7] Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal
    Fry, AM
    Jha, HC
    Lietman, TM
    Chaudhary, JSP
    Bhatta, RC
    Elliott, J
    Hyde, T
    Schuchat, A
    Gaynor, B
    Dowell, SF
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 35 (04) : 395 - 402
  • [8] Effects of amoxicilin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media
    Ghaffar, F
    Muniz, LS
    Katz, K
    Reynolds, J
    Smith, JL
    Davis, P
    Friedland, IR
    McCracken, GH
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 31 (04) : 875 - 880
  • [9] The epidemiology of pneumococcal infection in children in the developing world
    Greenwood, B
    [J]. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 1999, 354 (1384) : 777 - 785
  • [10] Henrichsen J, 1979, J INFECT, V1, P31, DOI [10.1016/S0163-4453(79)80029-8, DOI 10.1016/S0163-4453(79)80029-8]